Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
2027. jan. 15.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
2026. dec. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
[Reappraisal of the value of CD30 testing in the diagnosis and treatment of lymphoma].
2026. nov. 8.· Zhonghua bing li xue za zhi = Chinese journal of pathology· PUBMED
Publikáció
Immunohistochemical and clonality analyses of CD30+MUM1+ nonepitheliotropic T/NK-cell lymphomas in digits of dogs.
2026. okt. 26.· Veterinary pathology· PUBMED
Vizsgálat
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
2026. okt. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
Long-term Follow-up of Third-generation Anti-CD30 CAR T-cell Therapy in Relapsed/Refractory CD30+ Lymphomas: A Single-Arm, Multicenter, Phase I/II Trial.
2026. okt. 1.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Recurrent Hypoglycemia and Hypercalcemia As Presenting Features of CD30-Positive Peripheral T-cell Lymphoma, Not Otherwise Specified.
2026. okt. 1.· Cureus· PUBMED
Publikáció
Decreased cerebrospinal fluid TNFRSF8 (sCD30) confirmed as a biomarker of Huntington's disease progression.
2026. szept. 12.· Journal of neurology· PUBMED
Publikáció
CD30 expression in diffuse large B-cell lymphoma and primary mediastinal lymphoma: frequency, association with prognostic factors, and impact on survival.
2026. aug. 5.· Hematology, transfusion and cell therapy· PUBMED
Publikáció
Poorly differentiated lung adenocarcinomas with concurrent ALK and CD30 expression: a diagnostic pitfall mimicking ALK-positive anaplastic large-cell lymphoma.
2026. júl. 31.· Histopathology· PUBMED
Publikáció
Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.
2026. jún. 8.· Journal of clinical medicine· PUBMED
Publikáció
Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy.
2026. ápr. 27.· Cellular & molecular immunology· PUBMED
Publikáció
Type C Lymphomatoid Papulosis Following Immune Checkpoint Inhibition in a Melanoma Patient: A Reactive Mimicker of Cutaneous CD30+ Lymphoma.
2026. ápr. 1.· Dermatology practical & conceptual· PUBMED
Publikáció
CD30 knockout attenuates experimental colitis by reducing inflammatory cytokine production.
2026. márc. 13.· BMC immunology· PUBMED
Publikáció
CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30+ lymphomas.
2026. márc. 7.· Journal of translational medicine· PUBMED
Vizsgálat
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
2026. márc. 4.· PHASE1 · RECRUITING· CTGOV
Publikáció
Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma.
2026. febr. 24.· Oncology research· PUBMED
Publikáció
Immune Checkpoint Activity and Prognostic Roles of TNFRSF8, CD160, and TNFSF9 in Primary and Brain Metastatic NSCLC.
2026. jan. 22.· Asia-Pacific journal of clinical oncology· PUBMED
Publikáció
[Successful treatment of CD30-positive nodal follicular helper T-cell lymphoma, follicular type, with A-CHP and tucidinostat].
2026. jan. 1.· [Rinsho ketsueki] The Japanese journal of clinical hematology· PUBMED
Publikáció
JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders.
2026. jan. 1.· JAMA dermatology· PUBMED
Publikáció
A Case of Lymphomatoid Papulosis With CD15- and CD30-Positive Reed-Sternberg-Like Cells in CD8-Positive Mycosis Fungoides: Differential Diagnosis of Secondary Hodgkin Lymphoma and Large Cell Transformation of Mycosis Fungoides.
2025. dec. 10.· Cureus· PUBMED
Publikáció
CD30+ T-cell lymphoma following Chimeric Antigen Receptor T-cell therapy (CART-cell therapy): Diagnostic uncertainty in a postimmunotherapy setting.
2025. nov. 8.· JAAD case reports· PUBMED
Vizsgálat
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
2025. okt. 27.· PHASE1 · RECRUITING· CTGOV
Vizsgálat
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
2025. szept. 5.· NA · RECRUITING· CTGOV
Vizsgálat
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
2025. aug. 1.· PHASE1_PHASE2 · TERMINATED· CTGOV
Vizsgálat
Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma
2025. jan. 2.· PHASE1 · RECRUITING· CTIS
Publikáció
Prognostic and immunomodulatory roles of CD30 in diffuse large B-cell lymphoma: a cell-of-origin- and microenvironment-dependent paradigm.
2025. jan. 1.· Journal of clinical and experimental hematopathology : JCEH· PUBMED
Vizsgálat
Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressing an anti-CD30-chimeric antigen receptor with 4-1-BB and CD3z costimulatory sequences in patients with Classical Hodgkin lymphoma and non-Hodgkin CD30+ T cell lymphoma.
2024. dec. 17.· PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING· CTIS